The MSCP SPORE Developmental Research Program (DRP) provides seed funding to explore promising novel research in melanoma and other skin cancers, particularly by investigators not currently engaged in research in this area. The DRP solicits proposals twice a year and to use a peer-reviewed scoring system to prioritize proposals for funding. The DRP Directors and Executive Committee, Internal Advisory Board and External Advisory Board participate in the review process, together with the Patient Advocates and any additional experts who may be called upon if special reviewer expertise is necessary. During the past grant period, the MSCP SPORE funded 9 DRP projects in basic, translational, and clinical research. The DRP Directors track the progress of the successful applications and assign mentors to funded investigators to ensure that they obtain any needed services from the MSCP SPORE Cores (Administrative Core A, Biospecimen Core B, Biostatistics Core C, and Informatics Core D) and that they are effectively integrated into the SPORE program. Awardees present their research results to the SPORE investigators after one year of funding to be eligible for a second year of support. Progress toward translation as well as impact and innovation will determine whether DRP projects are found to merit promotion to full SPORE projects;in the past funding period, productive and innovative research funded by DRP awards to Drs. Hassane Zarour and Soldano Ferrone has been promoted to a full project. Project 3, in this renewal application. Awardees are also advised as appropriate in the preparation of grant applications for funding outside the SPORE mechanism and given access to SPORE Core resources to aid in this endeavor. DRP-supported research has led to 3 NCI awards (R01CA154728, R01CA157467, R01CA169118) and a pilot award funded by the University of Pittsburgh Clinical Translational Science Institute Basic to Clinical Collaborative Research Pilot Program. There are also several grant applications submitted or planned based on DRP results from the previous grant period, including an R21 and two additional R01 applications.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Dulmage, B O; Feng, H; Mirvish, E et al. (2015) Black cat in a dark room: the absence of a directly oncogenic virus does not eliminate the role of an infectious agent in cutaneous T-cell lymphoma pathogenesis. Br J Dermatol 172:1449-51
Sabbatino, Francesco; Wang, Yangyang; Wang, Xinhui et al. (2014) PDGFR? up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget 5:1926-41
Tarhini, Ahmad A; Edington, Howard; Butterfield, Lisa H et al. (2014) Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 9:e87705
Ng, Yuen-Keng; Lee, Jia-Ying; Supko, Kathryn M et al. (2014) Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res 24:207-18
Tarhini, Ahmad A; Shin, Donghoon; Lee, Sandra J et al. (2014) Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res 24:150-7
Pancoska, Petr; Kirkwood, John M; Bouros, Spyros et al. (2014) A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon. PLoS One 9:e86375
Tarhini, Ahmad A; Lin, Yan; Yeku, Oladapo et al. (2014) A four-marker signature of TNF-RII, TGF-?, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med 12:19
Geskin, Larisa J; Akilov, Oleg E; Lin, Yan et al. (2014) Distinct age-matched serum biomarker profiles in patients with cutaneous T-cell lymphoma. Exp Dermatol 23:598-600
Schowalter, Michael K; Dulmage, Brittany O; Ho, Jonhan et al. (2014) Comparative proteomic analysis reveals unique tumor protein composition among the melanoma subtypes pure desmoplastic and superficial spreading. Melanoma Res 24:397-400
McArthur, Grant A; Chapman, Paul B; Robert, Caroline et al. (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323-32

Showing the most recent 10 out of 59 publications